Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination

PLoS One. 2023 Sep 19;18(9):e0291670. doi: 10.1371/journal.pone.0291670. eCollection 2023.

Abstract

The COVID-19 antibody test was developed to investigate the humoral immune response to SARS-CoV-2 infection. In this study, we examined whether S antibody titers measured using the anti-SARS-CoV-2 IgG II Quant assay (S-IgG), a high-throughput test method, reflects the neutralizing capacity acquired after SARS-CoV-2 infection or vaccination. To assess the antibody dynamics and neutralizing potency, we utilized a total of 457 serum samples from 253 individuals: 325 samples from 128 COVID-19 patients including 136 samples from 29 severe/critical cases (Group S), 155 samples from 71 mild/moderate cases (Group M), and 132 samples from 132 health care workers (HCWs) who have received 2 doses of the BNT162b2 vaccinations. The authentic virus neutralization assay, the surrogate virus neutralizing antibody test (sVNT), and the Anti-N SARS-CoV-2 IgG assay (N-IgG) have been performed along with the S-IgG. The S-IgG correlated well with the neutralizing activity detected by the authentic virus neutralization assay (0.8904. of Spearman's rho value, p < 0.0001) and sVNT (0.9206. of Spearman's rho value, p < 0.0001). However, 4 samples (2.3%) of S-IgG and 8 samples (4.5%) of sVNT were inconsistent with negative results for neutralizing activity of the authentic virus neutralization assay. The kinetics of the SARS-CoV-2 neutralizing antibodies and anti-S IgG in severe cases were faster than the mild cases. All the HCWs elicited anti-S IgG titer after the second vaccination. However, the HCWs with history of COVID-19 or positive N-IgG elicited higher anti-S IgG titers than those who did not have it previously. Furthermore, it is difficult to predict the risk of breakthrough infection from anti-S IgG or sVNT antibody titers in HCWs after the second vaccination. Our data shows that the use of anti-S IgG titers as direct quantitative markers of neutralizing capacity is limited. Thus, antibody tests should be carefully interpreted when used as serological markers for diagnosis, treatment, and prophylaxis of COVID-19.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Blocking
  • Antibodies, Viral
  • BNT162 Vaccine*
  • COVID-19* / diagnosis
  • COVID-19* / prevention & control
  • Humans
  • Immunoglobulin G
  • SARS-CoV-2

Substances

  • BNT162 Vaccine
  • Antibodies, Blocking
  • Antibodies, Viral
  • Immunoglobulin G

Grants and funding

This research was partially supported by Japan Agency for Medical Research and Development under Grant Number JP20fk0108472 to TN and by Japan Society for the Promotion of Science Grants-in Aid for Scientific Research under Grant Number 22K15675 to ST. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.